Welcome to our dedicated page for Ctt Pharmaceutic news (Ticker: CTTH), a resource for investors and traders seeking the latest updates and insights on Ctt Pharmaceutic stock.
CTT Pharmaceutical Holdings Inc. (CTTH) pioneers advanced drug delivery systems using patented micelle technology and fast-dissolving oral strips. This dedicated news hub provides investors and healthcare professionals with essential updates on the company’s pharmaceutical innovations, strategic partnerships, and regulatory progress.
Access timely announcements about CTTH’s developments in pain management solutions, smoking cessation technologies, and chronic disease treatments. The curated collection features press releases covering patent approvals, clinical research milestones, and manufacturing advancements across global markets.
Key updates include progress reports on micelle-enhanced drug delivery platforms, collaborations with leading research institutions like Johns Hopkins University, and regulatory engagements with health authorities. All content is verified for accuracy and relevance to support informed decision-making.
Bookmark this page for consolidated access to CTTH’s latest corporate announcements, scientific breakthroughs, and market positioning updates. Check regularly for new developments in precision drug delivery systems and therapeutic applications.
CTT Pharmaceutical Holdings (OTCQB:CTTH) CEO Ryan Khouri provided a shareholder update regarding the company's ongoing grant applications and smoking cessation initiatives. The company has submitted applications for NIH and NSF grants before the January 6th deadline, with responses expected in April or May 2025. The review process is scheduled to begin in March.
The NIH grant would enable Johns Hopkins University to conduct clinical trials of CTT's innovative smoke-free low dose dissolvable strip, potentially creating the first new oral smoking cessation product in 40 years. The company has strengthened its team by adding two experienced grant specialists.
Khouri previously spoke at the FDA Headquarters in Maryland in October 2024 at an FDA and NIH event on Advancing Smoking Cessation Technology, receiving positive feedback. A conference call with shareholders is planned for April 2025, with the specific date to be announced.
CTT Pharmaceutical Holdings (OTCQB:CTTH) has successfully uplisted to the OTCQB Market effective March 9, 2025, trading under the ticker symbol 'CTTH'. The company's CEO is scheduled to release a shareholder update on Wednesday, March 12, 2025.
CTT Pharmaceutical Holdings (OTCQB:CTTH) has received approval from OTC Markets Group for uplisting its common shares to the OTCQB Market, effective March 10, 2025. The company will continue trading under the symbol 'CTTH'.
The uplisting to OTCQB, a premier marketplace for early-stage pharmaceutical companies developing new technology, is expected to enhance trading liquidity and provide a more streamlined trading experience for U.S. shareholders. Companies listed on OTCQB must maintain current reporting status and undergo annual PCAOB audits.
The company plans to make formal announcements regarding the uplisting on March 10, 2025, followed by a CEO news release to shareholders on March 12, 2025.
CTT Pharmaceutical Holdings (OTC PINK:CTTH) announced it anticipates receiving notification regarding its uplisting status to the OTCQB market during the week of March 3, 2025. The company stated it will keep shareholders informed of any developments regarding this potential market transition.
CTT Pharmaceutical Holdings (OTC PINK:CTTH) has received notification of an intention to grant from the European Patent Office (EPO) for additional claims to their original European Patent. The company already received an intention to grant for their micelle delivery technology but chose to further define and strengthen their patent specifically for diabetes-related drugs.
With the patent for the diabetes drug Liraglutide having expired, CTT plans to explore opportunities to utilize their micelle technology for this medication. The company believes their technology could provide an enhanced drug delivery system for pharmaceutical companies with current patented diabetes drugs and those in development.
CTT is actively strengthening their patents in both the United States and Europe and intends to file provisional patents in 2025 to further protect their technology. The company has committed to updating shareholders on additional provisional patents once filed and how they will support future development.
CTT Pharmaceutical Holdings (OTC:CTTH) has advanced past the initial round in its application for a National Science Foundation (NSF) grant for its patented fast-dissolving nicotine strips. The company is now among a few thousand remaining applicants from an initial pool of over 12,000. CTT expects to receive a response by late April.
The company's technology aims to address a significant public health issue, as cited by WHO statistics showing tobacco kills over 8 million people annually worldwide. According to CDC data, cigarette smoking causes more than 480,000 deaths yearly in the United States, representing nearly 1 in 5 deaths.
CEO Ryan Khouri highlighted that CTT's advancement in the NSF application process demonstrates the potential value of their technology in the tobacco industry. The company notes that there are currently no fast-dissolving, low-dose nicotine strips available in the market.
CTT Pharmaceuticals Holdings (OTC PINK:CTTH) has appointed Dr. Katherine Cole as an Independent Director. Dr. Cole brings extensive experience in biomedical research and academic leadership, including a Ph.D. in Pathology from the University of Maryland School of Medicine and three years at the National Cancer Institute (NIH) studying anti-cancer mechanisms.
Dr. Cole's credentials include positions as a biomedical scientist, professor, and vice Provost and Dean across four universities. She has authored twenty-two peer-reviewed papers and holds two patents related to a human liver cell line. Her research has been supported by grants from the National Science Foundation and the Howard Hughes Medical Institute.
CTT Pharmaceuticals Holdings (OTC:CTTH) has announced a significant reduction in its authorized share count, cutting it by 150 million shares from 300 million to 150 million shares. The change has been officially filed with the Delaware Division of Corporations and recorded by the company's stock issuer.
The company states this adjustment reflects its commitment to optimizing its capital structure and creating long-term shareholder value. Additionally, CTT is pursuing approval for an uplisting to the OTCQB market.
CTT Pharmaceuticals Holdings (OTC:CTTH) has submitted a grant application to the National Institutes of Health (NIH) to support further research and commercialization of their dissolvable nicotine strips. This submission complements an existing grant with Johns Hopkins University for clinical trials.
The initiative follows CEO Ryan Khouri's presentation at the FDA/NIH hearing for Advancing Smoking Cessation Technology. While the partnership with Johns Hopkins University remains a primary focus, CTT is pursuing additional NIH funding to advance their smoking cessation technology aimed at reducing risks of heart disease, stroke, and various cancers.
A decision on the NIH grant is expected in April 2025.
CTT Pharmaceutical Holdings (OTC:CTTH) and Johns Hopkins University have submitted a proposal for a $15 million NIH Grant to develop a smoking cessation product using CTT's patented technology. The NIH will review the proposal in April 2025.
The proposed product features fast-acting dissolvable nicotine strips that use less nicotine per dose compared to Nicorette gum and dissolve in seconds rather than 30 minutes. CTT plans to price the product competitively at or below Nicorette gum prices.
According to the World Health Organization, tobacco kills over 8 million people annually worldwide. The CDC reports smoking as the leading preventable cause of death in the United States, causing 480,000 deaths yearly. Johns Hopkins University will oversee the clinical trials if the grant is approved.
CEO Ryan Khouri has been invited to appear on Fox Business and Bloomberg regarding this grant and previously spoke at an FDA/NIH hearing about advancing smoking cessation technology.
FAQ
What is the current stock price of Ctt Pharmaceutic (CTTH)?
What is the market cap of Ctt Pharmaceutic (CTTH)?
